US 11,959,079 B2
Methods for treating apolipoprotein E4-associated disorders
Yadong Huang, San Francisco, CA (US); and Yaisa Andrews-Zwilling, San Francisco, CA (US)
Assigned to The J. David Gladstone Institutes, a testamentary trust established under the of Will of J. David Gladstone, California (CA)
Filed by The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone, San Francisco, CA (US)
Filed on Dec. 22, 2017, as Appl. No. 15/852,998.
Application 15/852,998 is a continuation of application No. 14/668,909, filed on Mar. 25, 2015, granted, now 9,885,039.
Application 14/668,909 is a continuation of application No. 12/958,057, filed on Dec. 1, 2010, abandoned.
Claims priority of provisional application 61/356,977, filed on Jun. 21, 2010.
Claims priority of provisional application 61/266,449, filed on Dec. 3, 2009.
Prior Publication US 2018/0195068 A1, Jul. 12, 2018
Int. Cl. A61K 48/00 (2006.01); A61K 31/7088 (2006.01); A61K 35/30 (2015.01); A61K 38/17 (2006.01); A61P 25/28 (2006.01); C12N 5/0797 (2010.01); C12N 15/113 (2010.01)
CPC C12N 15/113 (2013.01) [A61K 31/7088 (2013.01); A61K 35/30 (2013.01); A61K 38/1716 (2013.01); C12N 5/0623 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01); C12N 2510/00 (2013.01)] 7 Claims
 
1. A method of increasing the functionality of a GABAergic interneuron in the hilus of the hippocampus of an individual having at least one apolipoprotein E4 (apoE4) allele, the method comprising administering to the individual a tau-specific interfering nucleic acid that binds to a tau target and reduces the level of a tau polypeptide in the GABAergic interneuron, wherein the tau target is a contiguous stretch of at least 10 nucleotides of 5596-5807 of SEQ ID NO:2, wherein the tau-specific interfering nucleic acid is coupled to a carrier molecule that provides targeted delivery of the tau-specific interfering nucleic acid to the GABAergic interneuron.